丁丙诺啡纳洛酮治疗阿片类物质依赖患者的研究进展
作者：邢静静;周晓波;李静;
Author：
收稿日期： 年卷（期）页码：2015,30(06):-732-735
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：丁丙诺啡纳洛酮;物质依赖;丁丙诺啡;纳络酮;美沙酮;阿片类物质;研究进展
Key words：
基金项目：
中文摘要
丁丙诺啡纳洛酮是目前既能有效治疗阿片类物质依赖,又能进一步防止其滥用的药物。结合近年的研究文献,综述了其治疗阿片类物质依赖的最新研究进展。
参考文献
[1]Peles E,Schreiber S,Adelson M.15-Year survival and retention of patients in a general hospital-affliated methadone maintenance treatment(MMT)center in Israel[J].Drug Alcohol Depend,2010,107:141-148.
[2]Sofie M,Roonald F,Kathryn G.Utilizing bupreorphine-naloxone to treat illicit and prescription-opioid dependence[J].Neuropsychiatric Disease and Treatment,2014,10:587-598.
[3]Amass L,Ling W,Freese TE,et al.Bringing BuprenorphineNaloxone detoxification to community treatment providers:The NIDA Clinical trials network field experience[J].Am J Addic,2004,13:S42-S66.
[4]European Monitoring Centre for Drugs and Drug Addiction(EMCDDA).European Drug Report 2014:Trends and developments[R].Lisbon:EMCDDA,2014.
[5]Greenwald MK,Comer SD,Fiellin DA.Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder:Implications for clinical use and policy[J].Drug Alcohol Depend,2014,144:1-11.
[6]Canestrelli C,Marie N,Noble F.Rewarding or aversive effects of buprenorphine/naloxone combination(Suboxone)depend on conditioning trial duration[J].Int J Neuropsychopharmacol,2014,17:1367-1373.
[7]Jones JD,Sullivan MA,Vosburg SK,et al.Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users[J].Addict Biol,2014,20(4):784-798.
[8]刘霞,倪晓佳,李广兰,等.复方丁丙诺啡纳洛酮舌下片在阿片类药物依赖者中的药动学[J].中国医院药学杂志,2014,21:1808-1813.
[9]Lintzeris N,Leung SY,Dunlop AJ,et al.A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence[J].Drug Alcohol Depend,2013,131:119-126.
[10]Lyseng W,Katherine A.Buprenorphine/naloxone sublingual tablet[Zubsolv]:A guide to its use in the maintenance treatment of opioid dependence in the USA[J].Druds&Therapy Perspectives,2013,29(11):336-341.
[11]Rosenthal R,Ling W,Casadonte P,et al.Buprenorphine implants for treatment of opioid dependence:Randomized comparison to placebo and sublingual buprenorphine/naloxone[J].Addiction,2013,108:2141-2149.
[12]Basu D.Commentary on Rosenthal,et al.(2013):Buprenorphine implant-new hopes,old questions[J].Addiction,2013,108:2150-2151.
[13]Mattick RP,Breen C,Kimber J,et al.Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence[J].Cochrane Database Syst Rev,2014,2:CD002207.
[14]Soyka M,Kranzler HR,van den Brink W,et al.The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of substance use and related disorders.Part 2:Opioid dependence[J].World J Biol Psychiatry,2011,12:160-187.
[15]Hser YI,Saxon AJ,Huang D,et al.Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial[J].Addiction,2014,109:79-87.
[16]Community Care Behavioral Health Organization.Supporting recovery from opioid addiction:Community care best practice guide lines for Buprenorphine and Suboxone 2013[O].http://www.ct.gov/dmhas/lib/dmhas/publications/Community_Care_BP_Guidelines_for_Buprenorphine and Suboxone.pdf,2013.
[17]Centre for Addiction and Mental Health.Buprenorphine/Naloxone for opioid dependence:Clinical practice guideline[O].http://knowledgex.camh.net/primary_care/guidelines_materials/Documents/buprenorphine_naloxone_gdlns 2012.pdf,2013.
[18]Dijkstra BA,Krabbe PF,De Jong CA,et al.Prediction of withdrawal symptoms during opioid detoxification[J].J Opioid Manag,2008,4:311-319.
[19]Tompkins DA,Bigelow GE,Harrison JA,et al.Concurrent validation of the clinical opiate withdrawal scale(COWS)and singleitem indices against the Clinical Institute Narcotic Assessment(CINA)opioid withdrawal instruments[J].Drug Alcohol Depend,2009,105:154-159.
[20]Virani AS,Bezchlibnyk-Butler KZ,Jeffries JJ,et al.Clinical Handbook of Psychotropic Drugs[M].19th ed.Bern:Hogrefe and Huber,2012.
[21]Substance Abuse and Mental Health Services Administration(SAMHSA).Clinical guidelines for the use of Buprenorphine in the treatment of opioid addiction:A treatment improvement protocol(TIP)series 40[O].http://buprenorphine.samhsa.gov/Bup_Guidelines.pdf,2013.
[22]Gunderson EW,Levin FR,Rombone MM,et al.Improving temporal efficiency of outpatient buprenorphine induction[J].Am J Addict,2011,20:397-404.
[23]Ahmadi J.Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients[J].J Subst Abuse Treat,2003,24:217-220.
[24]Kakko J,Grnbladh L,Svanborg K,et al.A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence:A randomized controlled trial[J].Am J Psychiatry,2007,164:797-803.
[25]Fareed A,Vayalapalli S,Casarella J,et al.Treatment outcome for flexible dosing buprenorphine maintenance treatment[J].Am J Drug Alcohol Abuse,2012,38:155-160.
[26]Nielsen S,Hillhouse M,Thomas C,et al.A comparison of buprenorphine taper outcomes between prescription opioid and heroin users[J].J Addict Med,2013,7:33-38.
[27]Walley AY,Alperen JK,Cheng DM,et al.Office-based management of opioid dependence with buprenorphine:Clinical practices and barriers[J].J Gen Intern Med,2008,23(9):1393-1398.
[28]Kleber HD,Weiss RD,Anton RF,et al.Practice guidelines for the treatment of patients with substance use disorders,secondedition[M].Arling-ton(VA):American Psychiatric Association(APA),2013.
[29]国家禁毒委员会.2014中国禁毒报告[R].北京:国家禁毒委员会,2014.
[30]Hanon S,Seewald RM,Yang F,et al.Ventricular arrhythmias in patients treated with methadone for opioiddependence[J].J Interv Card Electrophysiol,2010,28:19-22.
【关闭】
